124 related articles for article (PubMed ID: 36581315)
1. Assay validation for vilanterol and its metabolites in human urine with application for doping control analysis.
Panchal T; Baldwin S; Østergaard M; Hansen ESH; Backer V; Hostrup M; Daley-Yates P
Drug Test Anal; 2023 May; 15(5):495-505. PubMed ID: 36581315
[TBL] [Abstract][Full Text] [Related]
2. Urine concentrations of vilanterol and its metabolites, GSK932009 and GW630200, after inhalation of therapeutic and supratherapeutic doses.
Østergaard M; Jessen S; Hansen ESH; Backer V; Panchal T; Baldwin S; Daley-Yates P; Hostrup M
Drug Test Anal; 2023 May; 15(5):516-528. PubMed ID: 36610030
[TBL] [Abstract][Full Text] [Related]
3. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
McKeage K
Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
Wolthers OD
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
[TBL] [Abstract][Full Text] [Related]
7. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
10. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
Hozawa S; Terada M; Haruta Y; Hozawa M
Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
[TBL] [Abstract][Full Text] [Related]
11. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
Kempsford R; Norris V; Siederer S
Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
[TBL] [Abstract][Full Text] [Related]
12. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA; Barnhart F; Brealey N; Brooks J; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Martinez FJ; Singh D; Tabberer M; Wise RA; Pascoe SJ;
N Engl J Med; 2018 May; 378(18):1671-1680. PubMed ID: 29668352
[TBL] [Abstract][Full Text] [Related]
13. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
Kempsford R; Allen A; Kelly K; Saggu P; Crim C
Br J Clin Pharmacol; 2014 Mar; 77(3):466-79. PubMed ID: 24093504
[TBL] [Abstract][Full Text] [Related]
14. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
[TBL] [Abstract][Full Text] [Related]
16. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
18. Fluticasone furoate/vilanterol: a review of its use in patients with asthma.
Syed YY
Drugs; 2015 Mar; 75(4):407-18. PubMed ID: 25648266
[TBL] [Abstract][Full Text] [Related]
19. Symptom control in patients with asthma using inhaled corticosteroids/long-acting β
Averell CM; Laliberté F; Germain G; Duh MS; Lima R; Mahendran M; Slade DJ
J Asthma; 2022 Sep; 59(9):1805-1818. PubMed ID: 34375568
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
Matera MG; Capuano A; Cazzola M
Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]